Sélectionner une page

Pierre MINIOU

Chief Operating Officer

UPR, ISR, Charcot-Marie-Tooth, CMT, inflammation, misfolded protein, phosphatase

InFlectis BioScience is a France-based clinical-stage company committed to the development of innovative therapeutics harnessing the Integrated Stress Response (ISR) for the treatment of a broad range of diseases. Dysregulation of ISR signaling has important pathologic consequences linked to neurodegenerative diseases, inflammation, and cancers. Harnessing the ISR by the pharmacological modulation of eIF2a dephosphorylation to restore the cellular homeostasis, is a new frontier pioneered by InFlectis BioScience. The company’s key value driver is IFB-088 currently in phase 1 for the treatment of CMT. InFlectis is also contemplating other promising therapeutic indications among neuro-degenerative diseases, inflammation, and cancers.